Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.

2.

Can the way we talk about cancer change how we interact with the disease?

3.

DBT Reduced Suicide Attempts in Adolescents with Bipolar Disorder.

4.

An Eye Surgeon's Unexpected Discovery of the "Before and After".

5.

Study recommends new grading system for invasive squamous cell carcinoma of the lung


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot